Atossa reports positive Phase 2 data for (Z)-endoxifen reducing breast density by up to 26.5%

ATOSSA THERAPEUTICS, INC.

Relative MBD reduction of 19.3% (1 mg) and 26.5% (2 mg) vs placebo in KARISMA-Endoxifen trial.
Mean plasma endoxifen: 5.18 ng/mL (1 mg) and 10.87 ng/mL (2 mg) after 1 month; stable at 3 and 6 months.
Drug-related discontinuations: 4 placebo, 5 (1 mg), 12 (2 mg); vasomotor symptoms minimal on 10-point scale.
Historical tamoxifen study: 10%+ density reduction associates with 62% lower 5-year breast cancer incidence.
Detailed results to be presented at San Antonio Breast Cancer Symposium in December 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.